See more : Evo Acquisition Corp. (EVOJW) Income Statement Analysis – Financial Results
Complete financial analysis of Medicine Man Technologies, Inc. (SHWZ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Medicine Man Technologies, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- First Solar, Inc. (0R06.L) Income Statement Analysis – Financial Results
- Sri KPR Industries Limited (SRIKPRIND.BO) Income Statement Analysis – Financial Results
- Chuco Co., Ltd. (2139.T) Income Statement Analysis – Financial Results
- SeaSpine Holdings Corporation (SPNE) Income Statement Analysis – Financial Results
- Hear AtLast Holdings, Inc. (HRAL) Income Statement Analysis – Financial Results
Medicine Man Technologies, Inc. (SHWZ)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.schwazze.com
About Medicine Man Technologies, Inc.
Medicine Man Technologies, Inc., doing business as Schwazze, operates as a cannabis company. It operates through three segments: Retail, Wholesale, and Other. The company offers cannabis products that include loose flower, concentrates, edibles, pre-rolls, topicals, and other associated cannabis products; and vape cartridges and syringes. As of March 14, 2022, it owned and operated 23 retail cannabis dispensaries under the Star Buds, Smoking Gun Apothecary, Emerald Fields, and Drift banner names in Denver and Colorado; and 10 medical retail cannabis dispensaries under the R. Greenleaf banner in New Mexico. The company also provides licensing and consulting, facility design, and facility management services; and Three A Light publication. In addition, it manufactures, wholesales, and retails various plant nutrients for cannabis; and supplies hydroponics and indoor gardening supplies. The company was incorporated in 2014 and is headquartered in Denver, Colorado.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 172.45M | 159.38M | 108.42M | 24.00M | 10.62M | 7.92M | 3.53M | 631.46K | 835.78K | 251.89K |
| Cost of Revenue | 96.42M | 74.35M | 59.07M | 17.23M | 7.62M | 2.58M | 1.30M | 462.18K | 209.75K | 72.00K |
| Gross Profit | 76.02M | 85.03M | 49.35M | 6.77M | 3.00M | 5.35M | 2.23M | 169.27K | 626.03K | 179.89K |
| Gross Profit Ratio | 44.09% | 53.35% | 45.52% | 28.23% | 28.27% | 67.47% | 63.10% | 26.81% | 74.90% | 71.42% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 70.93M | 64.16M | 38.94M | 29.68M | 16.47M | 4.40M | 7.13M | 1.01M | 519.88K | 193.15K |
| Selling & Marketing | 0.00 | -34.77M | 0.00 | 0.00 | 0.00 | 291.71K | 183.78K | 311.52K | 16.00K | 15.50K |
| SG&A | 70.93M | 64.16M | 38.94M | 29.68M | 16.47M | 4.69M | 7.31M | 1.32M | 535.88K | 208.64K |
| Other Expenses | 1.80M | 24.14K | 22.33M | 32.62K | 11.99M | 1.37M | -70.04K | 165.02K | 0.00 | 0.00 |
| Operating Expenses | 72.73M | 64.16M | 38.94M | 29.68M | 16.47M | 4.69M | 7.31M | 1.32M | 535.88K | 208.64K |
| Cost & Expenses | 169.16M | 138.51M | 98.01M | 46.90M | 24.08M | 7.27M | 8.62M | 1.78M | 745.62K | 280.64K |
| Interest Income | 0.00 | 30.14M | 7.01M | 41.46K | 31.91K | 30.00K | 30.00K | 14.02K | 8.07K | 3.12K |
| Interest Expense | 32.07M | 30.14M | 7.01M | 41.46K | 192.11K | 0.00 | 86.02K | 125.16K | 0.00 | 1.18K |
| Depreciation & Amortization | 20.93M | 11.55M | 8.58M | 476.59K | 61.71K | 81.96K | 63.74K | 17.37K | 6.62K | 561.00 |
| EBITDA | 37.52M | 38.12M | 3.47M | -19.80M | -13.55M | 1.61M | -5.23M | -1.42M | 96.77K | -30.40K |
| EBITDA Ratio | 21.76% | 20.02% | 3.20% | -104.26% | -89.16% | 9.64% | -143.42% | -177.48% | 11.58% | -9.95% |
| Operating Income | 3.29M | 20.89M | -5.11M | -22.90M | -13.46M | 2.17M | -5.24M | -1.15M | 90.15K | -28.75K |
| Operating Income Ratio | 1.91% | 13.11% | -4.71% | -95.43% | -126.80% | 27.39% | -148.34% | -182.45% | 10.79% | -11.41% |
| Total Other Income/Expenses | -18.10M | -16.42M | 8.51M | 2.59M | -476.76K | -638.50K | -145.22K | -312.18K | 8.07K | 1.94K |
| Income Before Tax | -14.81M | -3.57M | 18.92M | -20.32M | -17.56M | 1.53M | -5.38M | -1.46M | 98.22K | -26.81K |
| Income Before Tax Ratio | -8.59% | -2.24% | 17.45% | -84.65% | -165.36% | 19.33% | -152.46% | -231.89% | 11.75% | -10.64% |
| Income Tax Expense | 19.74M | 14.90M | 4.40M | -899.11K | -582.93K | 582.93K | 15.98K | 125.16K | 12.48K | 3.14K |
| Net Income | -34.55M | -18.47M | 14.52M | -19.42M | -16.98M | 948.92K | -5.38M | -1.46M | 85.75K | -29.95K |
| Net Income Ratio | -20.03% | -11.59% | 13.39% | -80.90% | -159.87% | 11.97% | -152.46% | -231.89% | 10.26% | -11.89% |
| EPS | -0.26 | -0.34 | 0.17 | -0.47 | -0.50 | 0.03 | -0.23 | -0.14 | 0.01 | 0.00 |
| EPS Diluted | -0.26 | -0.34 | -0.06 | -0.47 | -0.50 | 0.03 | -0.23 | -0.14 | 0.01 | 0.00 |
| Weighted Avg Shares Out | 64.54M | 53.64M | 43.34M | 41.22M | 33.74M | 27.77M | 22.99M | 10.23M | 9.91M | 9.84M |
| Weighted Avg Shares Out (Dil) | 64.54M | 53.64M | 101.37M | 41.22M | 33.74M | 27.77M | 22.99M | 10.23M | 9.91M | 9.97M |
Medicine Man Technologies Inc. (SHWZ) Q4 2022 Earnings Call Transcript
Cannabis Consolidation Continues
Medicine Man Technologies: Why I Am Buying This Stock
Schwazze: A Tiny Titan And Best Of Breed Operator In The Cannabis Space
Schwazze Executing Well In Difficult Economic Conditions
Medicine Man Technologies, Inc. (SHWZ) Q3 2022 Earnings Call Transcript
Schwazze Announces Virtual Town Hall Meeting
Schwazze: Signs Of Success For This Unusual Cannabis Company
Schwazze (SHWZ) CEO Justin Dye on Q2 2022 Results - Earnings Call Transcript
Cannabis Micro/Macro Picture
Source: https://incomestatements.info
Category: Stock Reports